These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

412 related articles for article (PubMed ID: 29429782)

  • 61. Visual evoked potentials of Niemann-Pick type C1 mice reveal an impairment of the visual pathway that is rescued by 2-hydroxypropyl-ß-cyclodextrin.
    Palladino G; Loizzo S; Fortuna A; Canterini S; Palombi F; Erickson RP; Mangia F; Fiorenza MT
    Orphanet J Rare Dis; 2015 Oct; 10():133. PubMed ID: 26458950
    [TBL] [Abstract][Full Text] [Related]  

  • 62. HPGCD outperforms HPBCD as a potential treatment for Niemann-Pick disease type C during disease modeling with iPS cells.
    Soga M; Ishitsuka Y; Hamasaki M; Yoneda K; Furuya H; Matsuo M; Ihn H; Fusaki N; Nakamura K; Nakagata N; Endo F; Irie T; Era T
    Stem Cells; 2015 Apr; 33(4):1075-88. PubMed ID: 25522247
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Combined therapy with cyclodextrin/allopregnanolone and miglustat improves motor but not cognitive functions in Niemann-Pick Type C1 mice.
    Hovakimyan M; Maass F; Petersen J; Holzmann C; Witt M; Lukas J; Frech MJ; Hübner R; Rolfs A; Wree A
    Neuroscience; 2013 Nov; 252():201-11. PubMed ID: 23948640
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Gender-Specific Effects of Two Treatment Strategies in a Mouse Model of Niemann-Pick Disease Type C1.
    Holzmann C; Witt M; Rolfs A; Antipova V; Wree A
    Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33802605
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Fine-tuned cholesterol solubilizer, mono-6-O-α-D-maltosyl-γ-cyclodextrin, ameliorates experimental Niemann-Pick disease type C without hearing loss.
    Yamada Y; Miwa T; Nakashima M; Shirakawa A; Ishii A; Namba N; Kondo Y; Takeo T; Nakagata N; Motoyama K; Higashi T; Arima H; Kurauchi Y; Seki T; Katsuki H; Okada Y; Ichikawa A; Higaki K; Hayashi K; Minami K; Yoshikawa N; Ikeda R; Ishikawa Y; Kajii T; Tachii K; Takeda H; Orita Y; Matsuo M; Irie T; Ishitsuka Y
    Biomed Pharmacother; 2022 Nov; 155():113698. PubMed ID: 36116252
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Synthesis, characterization, and evaluation of pluronic-based β-cyclodextrin polyrotaxanes for mobilization of accumulated cholesterol from Niemann-Pick type C fibroblasts.
    Collins CJ; McCauliff LA; Hyun SH; Zhang Z; Paul LN; Kulkarni A; Zick K; Wirth M; Storch J; Thompson DH
    Biochemistry; 2013 May; 52(19):3242-53. PubMed ID: 23560535
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Reduced cerebellar neurodegeneration after combined therapy with cyclodextrin/allopregnanolone and miglustat in NPC1: a mouse model of Niemann-Pick type C1 disease.
    Maass F; Petersen J; Hovakimyan M; Schmitt O; Witt M; Hawlitschka A; Lukas J; Rolfs A; Wree A
    J Neurosci Res; 2015 Mar; 93(3):433-42. PubMed ID: 25400034
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Cyclodextrins applied to the treatment of lysosomal storage disorders.
    Ishitsuka Y; Irie T; Matsuo M
    Adv Drug Deliv Rev; 2022 Dec; 191():114617. PubMed ID: 36356931
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Clinical disease characteristics of patients with Niemann-Pick Disease Type C: findings from the International Niemann-Pick Disease Registry (INPDR).
    Bolton SC; Soran V; Marfa MP; Imrie J; Gissen P; Jahnova H; Sharma R; Jones S; Santra S; Crushell E; Stampfer M; Coll MJ; Dawson C; Mathieson T; Green J; Dardis A; Bembi B; Patterson MC; Vanier MT; Geberhiwot T
    Orphanet J Rare Dis; 2022 Feb; 17(1):51. PubMed ID: 35164809
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Investigation of 2-Hydroxypropyl-β-Cyclodextrin Treatment in a Neuronal-Like Cell Model of Niemann-Pick Type C Using Quantitative Proteomics.
    Cougnoux A; Pergande MR; Serna-Perez F; Cologna SM
    J Am Soc Mass Spectrom; 2023 Apr; 34(4):668-675. PubMed ID: 36920149
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Neuronal gene repression in Niemann-Pick type C models is mediated by the c-Abl/HDAC2 signaling pathway.
    Contreras PS; Gonzalez-Zuñiga M; González-Hódar L; Yáñez MJ; Dulcey A; Marugan J; Seto E; Alvarez AR; Zanlungo S
    Biochim Biophys Acta; 2016 Feb; 1859(2):269-79. PubMed ID: 26603102
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Longitudinal Data in Patients with Niemann-Pick Type C Disease Under Combined High Intrathecal and Low Intravenous Dose of 2-hydroxylpropyl-β-cyclodextrin.
    Bountouvi E; Giorgi M; Papadopoulou A; Blennow K; Björkhem I; Tsirouda M; Kanellakis S; Fryganas A; Spanou M; Georgaki I; Asprogeraka S; Dinopoulos A
    Innov Clin Neurosci; 2021; 18(1-3):11-16. PubMed ID: 34150357
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Molecular Mind Games: The Medicinal Action of Cyclodextrins in Neurodegenerative Diseases.
    Braga SS
    Biomolecules; 2023 Apr; 13(4):. PubMed ID: 37189413
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Pharmacologic Treatment Assigned for Niemann Pick Type C1 Disease Partly Changes Behavioral Traits in Wild-Type Mice.
    Schlegel V; Thieme M; Holzmann C; Witt M; Grittner U; Rolfs A; Wree A
    Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27834854
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Chronic administration of an HDAC inhibitor treats both neurological and systemic Niemann-Pick type C disease in a mouse model.
    Alam MS; Getz M; Haldar K
    Sci Transl Med; 2016 Feb; 8(326):326ra23. PubMed ID: 26888431
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Stable or improved neurological manifestations during miglustat therapy in patients from the international disease registry for Niemann-Pick disease type C: an observational cohort study.
    Patterson MC; Mengel E; Vanier MT; Schwierin B; Muller A; Cornelisse P; Pineda M;
    Orphanet J Rare Dis; 2015 May; 10():65. PubMed ID: 26017010
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Treatment outcomes following continuous miglustat therapy in patients with Niemann-Pick disease Type C: a final report of the NPC Registry.
    Patterson MC; Mengel E; Vanier MT; Moneuse P; Rosenberg D; Pineda M
    Orphanet J Rare Dis; 2020 Apr; 15(1):104. PubMed ID: 32334605
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Visceral symptoms as a key diagnostic sign for the early infantile form of Niemann-Pick disease type C in a Russian patient: a case report.
    Degtyareva AV; Mikhailova SV; Zakharova EY; Tumanova EL; Puchkova AA
    J Med Case Rep; 2016 Jun; 10(1):143. PubMed ID: 27250337
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Induced Pluripotent Stem Cells for Disease Modeling and Evaluation of Therapeutics for Niemann-Pick Disease Type A.
    Long Y; Xu M; Li R; Dai S; Beers J; Chen G; Soheilian F; Baxa U; Wang M; Marugan JJ; Muro S; Li Z; Brady R; Zheng W
    Stem Cells Transl Med; 2016 Dec; 5(12):1644-1655. PubMed ID: 27484861
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Co-treatment with probucol does not improve lung pathology in hydroxypropyl-β-cyclodextrin-treated Npc1
    Erickson RP; Borbon IA
    J Appl Genet; 2019 May; 60(2):175-178. PubMed ID: 30815842
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.